Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again

Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.

Summary aggregated from CNBC's public RSS feed. The full reporting belongs to CNBC — please read it on their site.